With an eye on patients™
we are committed to developing solutions to help people facing serious eye disorders. At EyePoint Pharmaceuticals, you can see our dedication in action.
Menu
With an eye on patients™
we are committed to developing solutions to help people facing serious eye disorders. At EyePoint Pharmaceuticals, you can see our dedication in action.
Nancy Lurker
Chief Executive Officer & Board Director
Nancy Lurker leads our mission to improve the lives of people facing serious eye disorders. With more than 30 years in the pharmaceutical industry driving scientific and commercial innovation across public and private companies, from start-ups to the Fortune 500, she has a proven track record of maximizing the potential of new therapies and implementing US and global drug launches in diverse therapy areas.
Jay Duker, MD
President and Chief Operating Officer
Jay S. Duker, M.D., leads all clinical development, regulatory affairs, and operations. He is a leading retinal disease expert with more than 30 years in the field of ophthalmology focused on improving eyesight and preventing blindness, holding roles in clinical, research, business, start-ups, and academic settings.
George O. Elston
Chief Financial Officer
Mr Elston brings more than 25 years of diverse financial and senior leadership experience in the biopharmaceutical sector with both global publicly traded and privately held organizations.
Ron Honig, Esq.
Chief Legal Officer & Company Secretary
Ron Honig leads in-house counsel, leveraging his more than 30 years of experience in corporate governance, securities law compliance, and mergers and acquisitions to support the Company’s business priorities.
Scott Jones
Chief Commercial Officer
Scott Jones leads the commercialization of our innovative ophthalmic products. With significant experience in diverse roles commercializing drugs and devices globally, he is an expert in driving commercialization strategy and navigating healthcare policy.
Jennifer Leonard
Chief People Officer & SVP, IT
Ms Leonard has over 25 years of successful executive coaching, organizational effectiveness, leadership development, talent management, and culture development experience.
Dario Paggiarino, MD
Senior Vice President & Chief Medical Officer
Dario A. Paggiarino, M.D., leads Company Clinical Development programs and Medical Safety. He is a Medical and Clinical Development expert with more than 35 years of experience with small molecules, biologics and devices/drug-device combinations with focus in advancing therapeutics in the ocular space.
Said Saim, PhD
Senior Vice President & Chief Technology Officer
Said Saim, Ph.D., leads product Research & Development and manufacturing activities. He has more than 30 years of experience across the pharmaceutical industry with responsibilities including R&D and Manufacturing Operations.
Isabelle Lefebvre
Chief Regulatory Officer
Isabelle Lefebvre drives the Company’s regulatory strategy and compliance to bring innovative products to patients in the US and around the world. She is a regulatory expert with 30 years of experience across all phases of drug development including ophthalmic and ocular conditions.
Michael Pine
Chief Corporate Development & Strategy Officer
Michael Pine leads inorganic growth and strategy activities. He is an experienced leader in business development, having dedicated more than 20 years to licensing and M&A, advancing commercial, operational, and strategic efforts across both large and small companies in the pharmaceutical industry.
Board Chair
EyePoint and the EyePoint logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.
EyePoint and the EyePoint logo are registered trademarks of EyePoint Pharmaceuticals, Inc. With an Eye on Patients is a trademark of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.
EyePoint, the EyePoint logo, and Delivering Innovation to the Eye are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.
EyePoint, the EyePoint logo, Durasert, and DEXYCU are registered trademarks of EyePoint Pharmaceuticals, Inc. Verisome is a registered trademark of Ramscor, Inc. All other trademarks are the property of their respective owners.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.
EyePoint, the EyePoint logo, and Durasert are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.
EyePoint, the EyePoint logo, and the DEXYCU logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.
EyePoint, the EyePoint logo, and Durasert are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.
EyePoint, the EyePoint logo, DEXYCU, and the DEXYCU logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.
EyePoint, the EyePoint logo, Durasert, and DEXYCU are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.
EyePoint, the EyePoint logo, and DEXYCU are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2018-2022 EyePoint Pharmaceuticals, Inc. All Rights Reserved.